AveXis offers compelling reasons for a fast FDA OK for gene therapy to treat spinal muscular atrophy in infants
For most infants suffering from spinal muscular atrophy type 1, the chances are quite high that they could die or require constant respiratory assistance early on to allow them to keep breathing, with no motor function ability for simple things like sitting unassisted. Most die before the age of 4.
But in a small Phase I study of 15 patients treated with AveXis’ $AVXS gene therapy for SMA, all of the patients were able to reach 20 months without the need for constant respiratory support, or dying. And many achieved improvements in motor symptoms, speaking to the potential — though still unproven — of this as a once-and-done therapy for a rare but dire ailment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.